Snipr secures important US patent

The US Patent and Trademark Office has awarded the Danish biotech company a very important, and broadly protective, patent on its dual-killing mechanism, which is used in the firm’s first clinical candidate.

Christian Grøndahl, CEO of Snipr Biome | Photo: Snipr Biome/PR

Snipr Biome has completed a circle of patents in the US, according to the firm’s chief executive, Christian Grøndahl.

”This patent is the last pearl on the string of patents that we are making to protect our technology,” he tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs